Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review

Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review

Primary small cell neuroendocrine carcinoma of the prostate is extremely rare, highly aggressive, and has a very poor prognosis, with an overall survival typically not exceeding one year. Standard treatment is generally based on the regimen for small cell lung cancer (SCLC), with guidelines recommen...

Full description

Saved in:
Bibliographic Details
Main Authors: Xin Fei, Zhong Zheng, Zhen-ya Zhao, Da-wei Ren, Su-ying Wang, Shi-jie Ye, Lin-chun Liang, Da Li, Xiao-long Jia, Qi Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
small cell neuroendocrine carcinoma
NEPC
case report
anlotinib
tislelizumab
prostate cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510069/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items